Related Experiment Video
Updated: Aug 2, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Prevention of gastroduodenal complications in patients taking low-dose aspirin]
Ariane Chryssostalis1, Géraldine Marck, Jean Sibilia
1Service de Gastro-Entérologie, Hôpital Cochin-SVP, Université Paris V, 27, rue du Fbg-Saint-Jacques, 75014 Paris.
Abstract:
Use of low-dose aspirin is associated with an increased risk of gastroduodenal ulcers and upper gastrointestinal bleeding. The risk is increased by the old age and by cardiovascular and cerebrovascular diseases of the patients receiving low-dose aspirin. Combination with nonsteroidal anti-inflammatory drugs, corticosteroids or anticoagulant increases the risk of complications and should be avoided. Proton-pump inhibitor and eradication of Helicobacter pylori are not efficient in primary prevention of ulcer complications related to low-dose aspirin use. Patients at high risk of gastroduodenal complications due to age, morbidity or concomitant use of gastrotoxic therapy should be given prophylactic treatment. Assessment of what constitutes the most effective therapy (misoprostol, proton-pump inhibitor) should be defined in controlled trials. Among patients with Helicobacter pylori infection and a history of upper gastrointestinal bleeding who are taking low-dose aspirin, the eradication of Helicobacter pylori is equivalent to treatment with proton-pump inhibitor in preventing recurrent bleeding. Long term treatment with proton-pump inhibitor in addition to the eradication of Helicobacter pylori should be considered in patients who had ulcer complications related to the use of low-dose aspirin.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease III: Clinical Manifestations and Complications

